INVESTOR INFORMATION

Ovagen was established in 2000 as a privately funded R&D company.

Ovagen Group Limited is a privately owned company incorporated in the Republic of Ireland.

There are two wholly owned subsidiaries:
• Ovagen International Ltd. (Patent holding company)
• Ovagen Ltd., (Principle trading company).

UPDATES

If you would like to be notified of updates and progress relating to Ovagen, please enter your email address below. Your email address will not be passed on to any third party companies.

PRODUCT ROADMAP

2000
Concept defined, independent market research and initial investment

Ongoing R&D

2005
Proof of concept (2 genetic lines, >60% hatchability at first derivation to >80% in subsequent generations, fully sustainable breeding cycle)

2006
First press release to coincide with World Vaccine Congress 2006 in Lyon

2007
Extensive market research with large multinational phamaceutical companies confirms value proposition and market size.
Site acquired for new facilities
Detailed design and planning application for Phase I building.
New private investor funding.

2008
Secure investment from external financing/institutional investment for full scale manufacturing and 'go-to-market' strategy. Round I funding for €8m was completed in April.
Phase I planning application approved. Construction starts.
Detailed design of manufacturing facilities completed.
Planning application granted for all commercial production facilities.

2009
Total funding raised to date increases to €12m
Awarded EU Framework 7 funding for work on isolation of bone marrow stem cells (www.purstem.eu)
Commence large-scale production of GF birds.
Identification of strategic partners and completion of final funding round (€25m).

2010
Full scale production as a commercial business
Customer validation of GF eggs/cells
First sales of GF eggs

2011
Rapidly expanding production and sales of GF eggs direct to pharmaceutical companies.